Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection

Transplantation

Volumn 69, Issue 3, 2000, Pages 331-336

  Baan, Carla C ^a   Van Gelder, Teun ^a   Balk, Aggie H M M ^a   Knoop, Christiaan J ^a   Holweg, Cecile T J ^a   Maat, Lex P W M ^a   Weimar, Willem ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; PREDNISOLONE; RECEPTOR SUBUNIT; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2;

ALLOGRAFT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GRAFT FAILURE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0033998116     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200002150-00004     Document Type: Article

References (34)

1. Halloran PF, Miller LW. In vivo immunosuppressive mechanisms. J Heart Lung Transplant 1996; 15: 959.
2. Strom TB, Roy-Chaudhury P, Manfro R, et al. The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol 1996; 8: 688.
3. Nickerson P, Steiger J, Zheng XX, et al. Manipulation of cytokine networks in transplantation. Transplantation 1997; 63: 489.
4. Baan CC, Weimar W. Intragraft cytokine gene expression: implications for clinical transplantation. Transpl Int 1998; 11: 169.
5. Soulillou JP, Cantarovitch D, LeMauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antilymphocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
6. Friend PJ, Waldmann H, Cobbold S, et al. The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation. Transplantation 1991; 23: 1390.
7. Gelder van T, Zietse R, Mulder AH, et al. A double-blind placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995; 60: 248.
8. Gelder van T, Balk AHMM, Jonkman FAM, et al. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. Transplantation 1996; 62: 51.
9. Langrehr JM, Nüssler NC, Neuman U, et al. A prospective randomized trial comparing interleukin-2 receptor antibody versus anti-thymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Transplantation 1997: 63: 1772.
10. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748.
11. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Souilillou JP. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193.
12. Vincenti F, Kirkman R, Light S, et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
13. Gelder van T, Baan CC, Balk AHMM, et al. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans. Transplantation 1998; 65: 405.
14. Baan CC, Niesters HGM, Metselaar HJ, et al. Increased IL-15 mRNA expression after liver transplantation. Clin Transplant 1998; 12: 212.
15. Baan CC, Knoop CJ, Gelder van T, et al. Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation. Transplantation 1999; 67: 870.
16. Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, Strom TB. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 1997; 62: 543.
17. Li XC, Roy-Chaudhury P, Hancock WW, et al. IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T-cell growth factors in allograft rejection. J Immunol 1998; 161: 890.
18. Li XC, Schachter AD, Zand MS, et al. Differential expression of T-cell growth factors in rejecting murine and human renal allografts. Transplantation 1998; 66: 265.
19. Lin J-X, Migone TS, Tsang M, et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13 and IL-15. Immunity 1995; 2: 331.
20. Bamford RN, Tagaya Y, Waldmann TA. Interleukin-15: what it does and how it is controlled. Immunologist 1997; 5(2): 52.
21. International Society for Heart Transplantation. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Lung Transplant 1990; 9: 587.
22. Gelder van T, Daane CR, Vaessen LMB, et al. In vitro and in vivo effects of BT563, an anti-interleukin-2 receptor monoclonal antibody. Transpl Int 1994; 7: S556.
23. Strijbosch LWG, Buurman WA, Does RJMM, Zinken PH, Groenewegen G. Limiting dilution analysis: experimental design and statistical analysis. J Immunol Methods 1987; 97: 133.
24. Batuman OA, Ferrero AP, Diaz A, Berger B, Pomerantz RJ. Glucocorticoid-mediated inhibition of interleukin-2 receptor alpha and -beta subunit expression by human T cells. Immunopharmacology 1994; 27: 43.
25. Chae DW, Nosaka Y, Strom TB, Maslinski W. Distribution of IL-15 receptor α-chains on human peripheral blood mononuclear cells and effect of immunosuppressive drugs on receptor expression. J Immunol 1996; 157: 2813.
26. Strehlau J, Maslinski W, Chae D, Pavlakis M, Enrich JHH, Strom TB. Adjusting immunosuppression to the identification of T-cell activating mediators in rejecting transplants: a novel approach to rejection diagnosis and treatment. Transplant Proc 1998; 30: 2389.
27. Vacca A, Felli MP, Farine AR, et al. Glucocorticoid receptor-mediated suppression of the interleukin-2 gene expression through impairment of the cooperativity between nuclear factor of activated T-cells and AP-1 enhancer elements. J Exp Med 1992; 175: 637.
28. Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994; 57: 979.
29. Baan CC, Niesters HGM, Balk AHMM, et al. The intragraft cytokine mRNA pattern reflects the efficacy of steroid anti-rejection therapy. J Heart Lung Transplant 1996; 15: 1184.
30. Thèze J, Alzari PM, Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol Today 1996; 17: 481.
31. Tinubu SA, Hakimi J, Bailon P, et al. Humanized antibody directed to the IL-2 receptor β-chain prolongs primate cardiac allograft survival. J Immunol 1994; 153: 4330.
32. γ2a protein blocks DTH and enhances the acceptance of islet allografts. Transplantation 1998; 65: 257.
33. Kim YS, Maslinski W, Zheng XX, et al. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fcγ2a protein blocks delayed-type hypersensitivity. J Immunol 1998; 160-5742.
34. Ishli N, Takeshita T, Kimura Y, et al. Expression of the IL-2 receptor γ chain on various populations in human peripheral blood. Int Immunol 1994; 6: 1273.